Characterization of the tumor immune infiltrate in a colorectal syngeneic model dose with anti-PD-1 in combination with radiotherapy or PARP inhibitor

Sygnature Discovery presents new data evaluating how PD1 inhibition, alone and in combination with radiotherapy or PARP inhibition, influences immune cell infiltration and cytokine responses in the MC38 colorectal syngeneic colorectal model. The findings support the use of these models to investigate combination strategies and tumour immune modulation in preclinical immuno-oncology.

Study Highlights:

• Enhanced efficacy with PD1 inhibition and radiotherapy
• Distinct immune profiles with PD1 based combinations
• Niraparib modulates infiltration, but limits efficacy
• Cytokine analysis support immune modulation

Supporting PD1 Inhibition Strategies in Preclinical IO

These findings provide insight into how PD1 inhibition interacts with radiotherapy and PARP inhibition at the tumour microenvironment level. The MC38 model demonstrates utility in assessing immune checkpoint combinations, helping to shape rational IO drug development strategies.

Explore our Immuno-Oncology Expertise

Sygnature Discovery supports PD1 inhibition and combination strategies through our integrated preclinical immuno-oncology offering. Our capabilities span in vivo syngeneic models, immune phenotyping by flow cytometry and cytokine profiling to support mechanism-of-action and efficacy studies.